Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Cancer Conference Journal
Published in: International Cancer Conference Journal 4/2019

01-10-2019 | Computed Tomography | Case report

Testicular rhabdomyosarcoma after chemotherapy for metastatic germ cell tumors

Authors: Ryunosuke Nakagawa, Shuhei Aoyama, Satoko Urata, Mitsuo Ofude, Tohru Miyagi, Takao Nakashima, Yurie Okayama, Kazuyoshi Katayanagi

Published in: International Cancer Conference Journal | Issue 4/2019

Login to get access

Abstract

A 36-year-old male was referred to our hospital with left scrotal swelling. Computed tomography revealed a massive tumor in his left scrotum. The tumor extended along the gonadal vein extraperitoneally forming a massive tumor. Pathological examination showed a mixed-type germ cell tumor. Despite several chemotherapeutic treatments, the tumor continued to grow, and the patient died 28 months later after his first presentation at our institution. Autopsy revealed that the tumor comprised rhabdomyosarcoma and mature teratoma. We could not find useful tumor markers to facilitate the diagnosis of rhabdomyosarcoma. However, we recommend rebiopsy or palliative operation as options for re-diagnosis in case of resistant germ cell tumor. Here, we present a case of testicular tumor that exhibited different pathological examination results before and after treatment.
Literature
1.
Motzer Robert J, Amsterdam Alison, Prieto Victor et al (1998) Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol 159:133–138CrossRefPubMed
2.
3.
4.
Logothetis CJ, Samuels ML, Trindade A et al (1982) The growing teratoma syndrome. Cancer 50:1629–1635CrossRefPubMed
5.
Comiter CV, Kibel AS, Richie JP et al (1998) Prognostic features of teratomas with malignant transformation: a clinicopathological study of 21 cases. J Urol 159:859–863CrossRefPubMed
6.
Giannatempo P, Pond GR, Sonpavde G et al (2016) Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation: an international collaboration. J Urol 96:95–100CrossRef
7.
Oberlin O, Rey A, Lyden E et al (2008) Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 26:2384–2389CrossRefPubMedPubMedCentral
8.
Meza JL, Anderson J, Pappo AS et al (2006) Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol 24:3844–3851CrossRefPubMed
9.
Breneman JC, Lyden E, Pappo AS et al (2003) Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma—a report from the intergroup rhabdomyosarcoma study IV. J Clin Oncol 1:78–84CrossRef
10.
Spiess PE, Kassouf W, Brown GA et al (2007) Surgical management of growing teratoma syndrome. The J Urol 177:1330–1334CrossRefPubMed
11.
Mitsuru Miyachi, Kunihiko Tsuchiya, Hideki Yoshida et al (2010) Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcoma. Biochem Biophys Res Commun 10:89–93
12.
Masahiro M, Ikuyoshi H, Shigeyuki Y (2000) CA19-9 producing testicular tumor: a case report. Acta Urol Jpn 46:45–47
13.
Tsuruta T, Ogawa A, Ikado S et al (1997) CA19-9: a possible serum marker for embryonal carcinoma. Urol Int 58:20–24CrossRefPubMed
14.
Indraneel B, Vinay T, Sher S et al (2016) Role of urinary and serum carbohydrate antigen 19–9 as a biomarker in diagnosis of adult giant hydronephrosis. J Clin Diagn Res 10:8–11
15.
Meyer A, Kausch I, Kruger S et al (2004) Elevation of CA19-9 in giant hydronephrosis induced by a renal calculus. Urology 63:381–382CrossRefPubMed
16.
Korfel A, Fischer L, Foss H-D et al (2001) Testicular germ cell tumor with rhabdomyosarcoma successfully treated by disease-adapted chemotherapy including high-dose chemotherapy: case report and review of the literature. Bone Marrow Transplant 28:787–789CrossRefPubMed
Metadata
Title
Testicular rhabdomyosarcoma after chemotherapy for metastatic germ cell tumors
Authors
Ryunosuke Nakagawa
Shuhei Aoyama
Satoko Urata
Mitsuo Ofude
Tohru Miyagi
Takao Nakashima
Yurie Okayama
Kazuyoshi Katayanagi
Publication date
01-10-2019
Publisher
Springer Singapore
Published in
International Cancer Conference Journal / Issue 4/2019
Electronic ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-019-00378-2

Other articles of this Issue 4/2019

International Cancer Conference Journal 4/2019 Go to the issue

Case report

Hair regrowth using a properly fitted scalp cooling cap during adjuvant chemotherapy for breast cancer

Correction

Correction to: Multidisciplinary treatment for locally advanced breast cancer with internal mammary lymph node metastasis in an elderly patient

Case report

Remarkable effect of presurgical nivolumab on originally inoperable papillary renal cell carcinoma with tumor thrombus in inferior vena cava

Video article

Simultaneous robotic surgery with low anterior resection and prostatectomy/hysterectomy

Case report

Primary signet ring cell carcinoma of uterine cervix and related disease: two case reports and a review

Case report

Systemic steroid treatment can desensitize the skin reaction due to regorafenib in a recurrence colorectal cancer patient
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits